https://www.pharmaradar360.com/article/drug-label-update-acetaminophen-extra-strength-cd3f3091fa2d9e7ePharma Surgeen2026-07-15T00:00:00.000ZDrug label update: Acetaminophen Extra Strengthhttps://www.pharmaradar360.com/article/drug-label-update-allergy-relief-d593cd0779dcd03aPharma Surgeen2026-07-15T00:00:00.000ZDrug label update: Allergy Reliefhttps://www.pharmaradar360.com/article/die-kunst-des-im-wandel-seins-2077620d94aac233Pharma Surgeen2026-07-14T11:17:01.000ZDie Kunst des „Im Wandel-Seins“https://www.pharmaradar360.com/article/agenus-stock-doubles-as-biotech-narrows-phase-3-bet-ff97219e0d6ea283Pharma Surgeen2026-07-14T11:17:00.000ZAgenus stock doubles as biotech narrows Phase 3 bethttps://www.pharmaradar360.com/article/ai-biopharma-biossil-plans-to-advance-experimental-c-diff-drug-a822bb3813fed51aPharma Surgeen2026-07-14T11:07:14.000ZAI Biopharma Biossil Plans to Advance Experimental C. diff Drughttps://www.pharmaradar360.com/article/hepatitis-e-has-no-approved-treatments-as-atea-begins-human-trial-7ebed53cc2c67ad0Pharma Surgeen2026-07-14T11:00:00.000ZHepatitis E Has No Approved Treatments as Atea Begins Human Trialhttps://www.pharmaradar360.com/article/can-fite-s-namodenoson-in-phase-3-liver-cancer-study-pancreatic-trial-planned-3bcdb8879c5bea92Pharma Surgeen2026-07-14T11:00:00.000ZCan-Fite's Namodenoson in Phase 3 liver cancer study; pancreatic trial plannedhttps://www.pharmaradar360.com/article/new-map-shows-how-pharmaceuticals-support-jobs-health-and-growth-across-every-uk-d752ae113c772fa1Pharma Surgeen2026-07-14T10:59:54.000ZNew map shows how pharmaceuticals support jobs, health and growth across every UK nationhttps://www.pharmaradar360.com/article/catching-the-drift-how-wildfire-smoke-plumes-may-increase-cancer-risk-db8e7b2f5dceea70Pharma Surgeen2026-07-14T10:57:34.000ZCatching the Drift: How Wildfire Smoke Plumes May Increase Cancer Riskhttps://www.pharmaradar360.com/article/new-map-shows-how-pharmaceuticals-support-jobs-health-and-growth-across-every-uk-bd057dc21a414301Pharma Surgeen2026-07-14T10:55:59.000ZNew map shows how pharmaceuticals support jobs, health and growth across every UK nationhttps://www.pharmaradar360.com/article/european-biotech-chases-record-vc-funding-a3776ba34e3dfb6cPharma Surgeen2026-07-14T10:53:36.000ZEuropean biotech chases record VC fundinghttps://www.pharmaradar360.com/article/unpaid-carers-action-plan-recognise-refer-reach-9e6352a24c35b04aPharma Surgeen2026-07-14T10:42:29.000ZUnpaid carers action plan: recognise, refer, reachhttps://www.pharmaradar360.com/article/biotech-infrastructure-review-where-investment-is-flowing-84227229c8d8aad6Pharma Surgeen2026-07-14T10:32:14.000ZBiotech infrastructure review: where investment is flowinghttps://www.pharmaradar360.com/article/cathay-biotech-and-unit-file-trade-secret-infringement-lawsuit-8e062eb4314528afPharma Surgeen2026-07-14T10:32:04.000ZCathay Biotech And Unit File Trade Secret Infringement Lawsuithttps://www.pharmaradar360.com/article/atrium-s-first-prkag2-trial-to-evaluate-treatment-for-disease-cause-da250a8a72b76ed6Pharma Surgeen2026-07-14T10:30:00.000ZAtrium's First PRKAG2 Trial to Evaluate Treatment for Disease Causehttps://www.pharmaradar360.com/article/hansoh-pharmaceutical-pharma-announces-license-collaboration-and-strategic-inves-77d6f1deca86eb20Pharma Surgeen2026-07-14T10:20:05.000ZHansoh Pharmaceutical : PHARMA ANNOUNCES LICENSE COLLABORATION AND STRATEGIC INVESTMENT WITH AVERE FOR ORAL IL‑23 ASSET HS‑20118https://www.pharmaradar360.com/article/shampoo-chemicals-in-your-milk-2-crore-adulteration-racket-exposed-in-maharashtr-8c2b6e5c75ba4a29Pharma Surgeen2026-07-14T10:13:01.000ZShampoo, chemicals in your milk? ₹2 crore adulteration racket exposed in Maharashtrahttps://www.pharmaradar360.com/article/sabto-reports-and-guidance-documents-a9d6712ad78069caPharma Surgeen2026-07-14T10:12:20.000ZSaBTO reports and guidance documentshttps://www.pharmaradar360.com/article/sabto-annual-report-2024-to-2025-6664dca759a80d04Pharma Surgeen2026-07-14T10:12:14.000ZSaBTO annual report 2024 to 2025https://www.pharmaradar360.com/article/centogene-takes-ownership-in-pearl-medical-analysis-lab-in-abu-dhabi-069efc0d7654e28fPharma Surgeen2026-07-14T10:09:41.000ZCENTOGENE takes ownership in Pearl Medical Analysis Lab in Abu Dhabihttps://www.pharmaradar360.com/article/effect-edesa-biotech-inc-sec-filing-1b6bb1a899d47164Pharma Surgeen2026-07-14T10:05:42.000Z[EFFECT] Edesa Biotech, Inc. SEC Filinghttps://www.pharmaradar360.com/article/swimmer-archie-goodburn-goes-from-graduation-to-the-games-50dd2067a0017dcaPharma Surgeen2026-07-14T10:02:19.000ZSwimmer Archie Goodburn goes from graduation to the Gameshttps://www.pharmaradar360.com/article/northwestern-medicine-performs-first-known-quadruple-organ-transplant-involving-29fff7716c5b0f67Pharma Surgeen2026-07-14T10:00:00.000ZNorthwestern Medicine performs first known quadruple-organ transplant involving retransplanted lungshttps://www.pharmaradar360.com/article/spero-s-1-1b-antibody-deal-targets-two-immune-diseases-a0f7d204e6018177Pharma Surgeen2026-07-14T10:00:00.000ZSpero’s $1.1B antibody deal targets two immune diseaseshttps://www.pharmaradar360.com/article/after-4-7b-sale-to-novo-nordisk-former-akero-team-announces-new-i-i-company-with-572baff3d3ab062bPharma Surgeen2026-07-14T10:00:00.000ZAfter $4.7B sale to Novo Nordisk, former Akero team announces new I&I company with China drughttps://www.pharmaradar360.com/article/cambridge-biotech-strikes-1-1b-deal-with-chinese-partner-shifts-to-immunology-149b3bddbee9c30bPharma Surgeen2026-07-14T10:00:00.000ZCambridge biotech strikes $1.1B deal with Chinese partner, shifts to immunologyhttps://www.pharmaradar360.com/article/arbs-green-biotech-innovator-with-key-partnerships-in-cosmetics-and-agriculture-18cd737ba40422ffPharma Surgeen2026-07-14T09:58:27.000ZARBS: Green biotech innovator with key partnerships in cosmetics and agriculturehttps://www.pharmaradar360.com/article/pneumococcal-vaccination-programmes-for-infants-adults-and-individuals-at-increa-8050db2fd0e7d296Pharma Surgeen2026-07-14T09:57:07.000ZPneumococcal vaccination programmes for infants, adults and individuals at increased clinical riskhttps://www.pharmaradar360.com/article/elevara-medicines-appoints-biotech-veteran-as-ceo-fd246bfb71da8600Pharma Surgeen2026-07-14T09:47:06.000ZElevara Medicines appoints biotech veteran as CEOhttps://www.pharmaradar360.com/article/annexon-perfect-complement-to-a-speculative-biotech-portfolio-nasdaq-annx-658c587052e9a219Pharma Surgeen2026-07-14T09:43:52.000ZAnnexon: Perfect Complement To A Speculative Biotech Portfolio (NASDAQ:ANNX)https://www.pharmaradar360.com/article/travellers-reminded-to-take-precautions-to-avoid-infections-abroad-this-summer-4601fa70feb533c8Pharma Surgeen2026-07-14T09:38:09.000ZTravellers reminded to take precautions to avoid infections abroad this summerhttps://www.pharmaradar360.com/article/digital-process-development-for-cell-and-gene-therapy-d8b4e193c258b7c8Pharma Surgeen2026-07-14T09:35:00.000ZDigital process development for cell and gene therapyhttps://www.pharmaradar360.com/article/25-transfers-in-21-years-who-is-tukaram-mundhe-ias-officer-leading-maharashtra-s-17c166fff07b641cPharma Surgeen2026-07-14T09:27:39.000Z25 Transfers in 21 Years: Who is Tukaram Mundhe? IAS Officer Leading Maharashtra’s Food Safety Crackdownhttps://www.pharmaradar360.com/article/germany-approves-healthcare-costs-overhaul-despite-significant-pharma-opposition-392d13fc25f07602Pharma Surgeen2026-07-14T09:22:30.000ZGermany approves healthcare costs overhaul despite significant pharma oppositionhttps://www.pharmaradar360.com/article/cathie-wood-is-loading-up-on-this-biotech-stock-is-it-a-no-brainer-buy-e3e52df111bc10c3Pharma Surgeen2026-07-14T09:22:24.000ZCathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?https://www.pharmaradar360.com/article/donald-trump-s-drug-pricing-deals-are-reshaping-big-pharma-here-s-what-that-mean-a171df846ecb22a9Pharma Surgeen2026-07-14T09:20:18.000ZDonald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibbhttps://www.pharmaradar360.com/article/field-safety-notices-6-to-10-july-2026-46da3042a83bf244Pharma Surgeen2026-07-14T09:19:00.000ZField Safety Notices: 6 to 10 July 2026https://www.pharmaradar360.com/article/cathie-wood-is-loading-up-on-this-biotech-stock-is-it-a-no-brainer-buy-eb4776f026fe0d4cPharma Surgeen2026-07-14T09:17:26.000ZCathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?https://www.pharmaradar360.com/article/reports-of-cases-of-tb-to-uk-enhanced-tuberculosis-surveillance-systems-2000-to-7bbe0add77b9e3d5Pharma Surgeen2026-07-14T09:14:08.000ZReports of cases of TB to UK enhanced tuberculosis surveillance systems 2000 to 2025https://www.pharmaradar360.com/article/molecular-map-of-liver-disease-could-transform-how-masld-is-diagnosed-and-monito-6db1b03b80ce7287Pharma Surgeen2026-07-14T09:09:42.000ZMolecular map of liver disease could transform how MASLD is diagnosed and monitoredhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-9-august-2026-9b85cffeadf04a35Pharma Surgeen2026-07-14T09:09:22.000ZWeekly all-cause mortality surveillance: week ending 9 August 2026https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-33-report-data-to-week-32-dat-1333b67e4538d4d8Pharma Surgeen2026-07-14T09:09:13.000ZNational flu and COVID-19 surveillance report, week 33 report: data to week 32 (data up to 9 August 2026)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-2-august-2026-9727509b061a9ef9Pharma Surgeen2026-07-14T09:09:03.000ZWeekly all-cause mortality surveillance: week ending 2 August 2026https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-jun-6e405552d2e63be0Pharma Surgeen2026-07-14T09:08:57.000ZRespiratory syncytial virus (RSV) older adults vaccination coverage in England: June 2026https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-march-2-30e801b2e4b499e7Pharma Surgeen2026-07-14T09:08:49.000ZRespiratory syncytial virus (RSV) maternal vaccination coverage in England: March 2026https://www.pharmaradar360.com/article/138-doktorurkunden-vier-stiftungspreise-und-ein-nobelpreistrager-9809bcbb627dffcfPharma Surgeen2026-07-14T09:08:47.000Z138 Doktorurkunden, vier Stiftungspreise und ein Nobelpreisträgerhttps://www.pharmaradar360.com/article/china-resources-pharmaceutical-refreshes-board-with-new-non-executive-director-c73ac853c6b6394dPharma Surgeen2026-07-14T09:06:36.000ZChina Resources Pharmaceutical Refreshes Board With New Non-Executive Directorhttps://www.pharmaradar360.com/article/why-cross-sector-collaboration-in-ai-is-the-key-to-unlocking-new-medicines-23b1a9bf1c6b4888Pharma Surgeen2026-07-14T09:06:35.000ZWhy cross-sector collaboration in AI is the key to unlocking new medicineshttps://www.pharmaradar360.com/article/increase-uptime-with-recommended-parts-inventory-5a17317e9534ef3dPharma Surgeen2026-07-14T09:05:56.000ZIncrease uptime with Recommended Parts Inventoryhttps://www.pharmaradar360.com/article/donald-trump-s-drug-pricing-deals-are-reshaping-big-pharma-here-s-what-that-mean-2cb7908e39c94257Pharma Surgeen2026-07-14T09:04:03.000ZDonald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibbhttps://www.pharmaradar360.com/article/the-ai-arms-race-in-administrative-health-care-4b9ac3df0d4d8ce9Pharma Surgeen2026-07-14T09:00:00.000ZThe AI Arms Race in Administrative Health Carehttps://www.pharmaradar360.com/article/americans-for-safe-and-effective-medicines-launches-to-protect-patients-from-ill-893b0b035efe4c79Pharma Surgeen2026-07-14T09:00:00.000ZAmericans for Safe and Effective Medicines Launches to Protect Patients from Illegal Mass Compounding, Counterfeit Drugs, and Misleading Marketinghttps://www.pharmaradar360.com/article/acg-metals-rockfire-resources-sunda-energy-cellbxhealth-poolbeg-pharmaceutical-35990f01485a3cf0Pharma Surgeen2026-07-14T08:57:48.000ZACG Metals, Rockfire Resources, Sunda Energy, CelLBxHealth, Poolbeg Pharmaceuticalhttps://www.pharmaradar360.com/article/celltrion-ends-europe-phase-3-for-keytruda-biosimilar-as-regulators-ease-rules-c-c0f4becfabc5316ePharma Surgeen2026-07-14T08:55:00.000ZCelltrion ends Europe phase 3 for Keytruda biosimilar as regulators ease rules - CHOSUNBIZhttps://www.pharmaradar360.com/article/even-though-there-are-world-class-large-hospitals-it-is-difficult-to-secure-glob-feb893f0decbc39fPharma Surgeen2026-07-14T08:51:17.000ZEven though there are world-class large hospitals, it is difficult to secure global competitiveness..https://www.pharmaradar360.com/article/regulator-eases-biosimilar-approval-requirements-waiving-some-phase-3-trial-data-788b46d0ac4e12efPharma Surgeen2026-07-14T08:42:32.000ZRegulator eases biosimilar approval requirements, waiving some phase 3 trial datahttps://www.pharmaradar360.com/article/biotech-ushers-in-new-class-of-personal-care-ingredients-60682910004f85c2Pharma Surgeen2026-07-14T08:42:19.000ZBiotech ushers in new class of personal care ingredientshttps://www.pharmaradar360.com/article/guidance-in-vitro-diagnostic-point-of-care-test-devices-8cf6f19f1fa74a70Pharma Surgeen2026-07-14T08:40:53.000ZGuidance: In vitro diagnostic point-of-care test deviceshttps://www.pharmaradar360.com/article/elevara-medicines-appoints-biotech-veteran-as-ceo-ee518c890bb23dffPharma Surgeen2026-07-14T08:40:28.000ZElevara Medicines Appoints Biotech Veteran as CEOhttps://www.pharmaradar360.com/article/new-trial-offers-hope-for-people-with-rare-adrenal-cancer-c6685133e6a6ac55Pharma Surgeen2026-07-14T08:38:03.000ZNew trial offers hope for people with rare adrenal cancerhttps://www.pharmaradar360.com/article/pneumococcal-vaccination-expansion-of-eligibility-to-people-experiencing-homeles-44e10e0781988674Pharma Surgeen2026-07-14T08:30:03.000ZPneumococcal vaccination: expansion of eligibility to people experiencing homelessnesshttps://www.pharmaradar360.com/article/laboratory-confirmed-zika-virus-disease-cases-statistics-ce9ca844e3bbb799Pharma Surgeen2026-07-14T08:30:03.000ZLaboratory-confirmed Zika virus disease cases: statisticshttps://www.pharmaradar360.com/article/laboratory-confirmed-typhoid-and-paratyphoid-cases-statistics-32ed718d28bc48dfPharma Surgeen2026-07-14T08:30:03.000ZLaboratory-confirmed typhoid and paratyphoid cases: statisticshttps://www.pharmaradar360.com/article/imported-malaria-in-the-uk-statistics-6d329ecef4fc16e6Pharma Surgeen2026-07-14T08:30:03.000ZImported malaria in the UK: statisticshttps://www.pharmaradar360.com/article/laboratory-confirmed-dengue-cases-statistics-8d90a3faa0277af2Pharma Surgeen2026-07-14T08:30:03.000ZLaboratory-confirmed dengue cases: statisticshttps://www.pharmaradar360.com/article/chikungunya-epidemiology-in-england-wales-and-northern-ireland-b54799970926b993Pharma Surgeen2026-07-14T08:30:03.000ZChikungunya: epidemiology in England, Wales and Northern Irelandhttps://www.pharmaradar360.com/article/astrazeneca-to-license-lung-cancer-drug-from-china-s-dizal-pharmaceutical-e00044dfaf25b2efPharma Surgeen2026-07-14T08:24:57.000ZAstraZeneca to license lung cancer drug from China's Dizal Pharmaceuticalhttps://www.pharmaradar360.com/article/it-s-worth-another-try-campaign-from-terrence-higgins-trust-ddeb33985c6e33d1Pharma Surgeen2026-07-14T08:11:10.000ZIt’s Worth Another Try campaign from Terrence Higgins Trusthttps://www.pharmaradar360.com/article/elevara-medicines-appoints-biotech-veteran-as-ceo-cfc8e71c128d4ca4Pharma Surgeen2026-07-14T08:10:34.000ZElevara Medicines Appoints Biotech Veteran as CEOhttps://www.pharmaradar360.com/article/a-study-identifies-a-relationship-between-cognitive-reserve-and-brain-structure-c3e9ead9ed0c4ef0Pharma Surgeen2026-07-14T08:00:00.000ZA study identifies a relationship between cognitive reserve and brain structure in young people at risk of psychosishttps://www.pharmaradar360.com/article/stocks-in-play-oncolytics-biotech-inc-fbe1074d8b2acddePharma Surgeen2026-07-14T07:51:00.000ZStocks in play: Oncolytics Biotech Inchttps://www.pharmaradar360.com/article/middle-east-pharmaceutical-grade-polyethylene-glycol-market-analysis-forecast-si-b5d6c3326357abacPharma Surgeen2026-07-14T07:48:57.000ZMiddle East Pharmaceutical Grade Polyethylene Glycol - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/ny-satsning-ska-starka-arbetet-mot-atstorningar-i-vastra-gotaland-c7cf5e72b9c38992Pharma Surgeen2026-07-14T07:48:41.000ZNy satsning ska stärka arbetet mot ätstörningar i Västra Götalandhttps://www.pharmaradar360.com/article/millions-of-unpaid-carers-to-get-recognition-and-earlier-support-dc45dda3a0797942Pharma Surgeen2026-07-14T07:45:06.000ZMillions of unpaid carers to get recognition and earlier supporthttps://www.pharmaradar360.com/article/celltrion-ends-keytruda-biosimilar-phase-3-trial-in-europe-early-77bcf35752cd71a6Pharma Surgeen2026-07-14T07:44:05.000ZCelltrion Ends Keytruda Biosimilar Phase 3 Trial in Europe Earlyhttps://www.pharmaradar360.com/article/pharmaceutical-manufacturing-validation-batch-integrity-and-what-a-cyber-inciden-d902f3316c9ecc8ePharma Surgeen2026-07-14T07:33:47.000ZPharmaceutical manufacturing: Validation, batch integrity, and what a cyber incident actually costshttps://www.pharmaradar360.com/article/zacks-industry-outlook-mckesson-cardinal-west-pharmaceutical-align-and-henry-b97b7e2e3854bec9Pharma Surgeen2026-07-14T07:31:00.000ZZacks Industry Outlook McKesson, Cardinal, West Pharmaceutical, Align and Henryhttps://www.pharmaradar360.com/article/laboratory-operations-and-technology-innovator-chris-clendening-joins-precision-470f37269fb622f5Pharma Surgeen2026-07-14T07:30:01.000ZLaboratory Operations and Technology Innovator Chris Clendening Joins Precision for Medicine to Lead Specialty Labshttps://www.pharmaradar360.com/article/astrazeneca-strikes-exclusive-licensing-deal-with-dizal-pharmaceutical-0a5c165d90f8da0cPharma Surgeen2026-07-14T07:20:10.000ZAstrazeneca strikes exclusive licensing deal with Dizal Pharmaceuticalhttps://www.pharmaradar360.com/article/okyo-pharma-moves-urcosimod-into-global-phase-3-trial-2bad6f7ff37c09d6Pharma Surgeen2026-07-14T07:18:45.000ZOKYO Pharma moves urcosimod into global phase 3 trialhttps://www.pharmaradar360.com/article/la-ema-recomienda-retirar-la-autorizacion-de-comercializacion-de-avacopan-tavneo-9690088523e2f7e1Pharma Surgeen2026-07-14T07:15:30.000ZLa EMA recomienda retirar la autorización de comercialización de avacopan (Tavneos)https://www.pharmaradar360.com/article/la-aemps-informa-de-las-nuevas-medidas-para-prevenir-el-dano-hepatico-con-avacop-389ff0fec745a2b4Pharma Surgeen2026-07-14T07:13:28.000ZLa AEMPS informa de las nuevas medidas para prevenir el daño hepático con avacopan (Tavneos)https://www.pharmaradar360.com/article/biovica-receives-ninth-work-order-from-a-leading-global-pharmaceutical-customer-873a444bfab5cf96Pharma Surgeen2026-07-14T07:10:00.000ZBiovica Receives Ninth Work Order From a Leading Global Pharmaceutical Customerhttps://www.pharmaradar360.com/article/esg-transforming-the-pharmaceutical-supply-chain-4026dd6232429e44Pharma Surgeen2026-07-14T07:02:09.000ZESG: transforming the pharmaceutical supply chainhttps://www.pharmaradar360.com/article/nominations-open-for-unmc-s-highest-research-honors-03f587187911e746Pharma Surgeen2026-07-14T07:00:00.000ZNominations open for UNMC’s highest research honorshttps://www.pharmaradar360.com/article/retirement-reception-july-28-for-shantaram-joshi-phd-96981807e96297cfPharma Surgeen2026-07-14T06:58:00.000ZRetirement reception July 28 for Shantaram Joshi, PhDhttps://www.pharmaradar360.com/article/college-of-public-health-inducts-new-delta-omega-members-3bb39a6c644afae0Pharma Surgeen2026-07-14T06:56:00.000ZCollege of Public Health inducts new Delta Omega membershttps://www.pharmaradar360.com/article/geospatial-approaches-for-mapping-zero-dose-prevalence-and-routine-childhood-imm-cb3df4e76aa8c9edPharma Surgeen2026-07-14T06:53:53.000ZGeospatial approaches for mapping zero-dose prevalence and routine childhood immunisation coverage in low- and lower-middle-income countries: A scoping reviewhttps://www.pharmaradar360.com/article/excellence-in-fluorinated-pharmaceutical-intermediates-baokai-pharma-sets-the-be-7af718492feee05aPharma Surgeen2026-07-14T06:48:03.000ZExcellence in Fluorinated Pharmaceutical Intermediates – Baokai Pharma Sets the Benchmark in High-End Fluorochemicals - ChemNethttps://www.pharmaradar360.com/article/bavarian-nordic-partner-applies-for-approval-of-chikungunya-vaccine-in-brazil-f3f58affdf89bd9fPharma Surgeen2026-07-14T06:20:23.000ZBavarian Nordic partner applies for approval of chikungunya vaccine in Brazilhttps://www.pharmaradar360.com/article/astrazeneca-to-license-lung-cancer-drug-from-china-s-dizal-pharmaceutical-7c8061545cdbdc9fPharma Surgeen2026-07-14T06:19:00.000ZAstraZeneca to license lung cancer drug from China's Dizal Pharmaceuticalhttps://www.pharmaradar360.com/article/south-korea-eases-biosimilar-rules-to-cut-trials-time-and-costs-chosunbiz-5b588d12e164a82fPharma Surgeen2026-07-14T06:18:00.000ZSouth Korea eases biosimilar rules to cut trials, time, and costs - CHOSUNBIZhttps://www.pharmaradar360.com/article/agenus-secures-340-million-to-fund-phase-3-robbin-trial-ab1f1902be3a1da3Pharma Surgeen2026-07-14T06:13:38.000ZAgenus Secures $340 Million to Fund Phase 3 ROBBIN Trialhttps://www.pharmaradar360.com/article/number-of-employees-of-nkgen-biotech-inc-otc-nkgnw-1b0c1a902cca9effPharma Surgeen2026-07-14T06:11:40.000ZNumber of employees of NKGen Biotech Inc. – OTC:NKGNWhttps://www.pharmaradar360.com/article/delivering-life-how-resilience-and-innovation-define-the-future-of-pharmaceutica-90f5a58a9e4b8944Pharma Surgeen2026-07-14T06:02:33.000ZDelivering life: How resilience and innovation define the future of pharmaceutical logisticshttps://www.pharmaradar360.com/article/is-your-quality-system-built-for-2026-s-new-regulatory-reality-8079afceff5750acPharma Surgeen2026-07-14T06:00:00.000ZIs your quality system built for 2026’s new regulatory reality?https://www.pharmaradar360.com/article/the-fda-s-psychedelic-guidance-is-really-a-study-design-reckoning-20193ba8aa1c10abPharma Surgeen2026-07-14T05:54:16.000ZThe FDA’s Psychedelic Guidance Is Really a Study-Design Reckoninghttps://www.pharmaradar360.com/article/biosimilar-development-time-and-costs-to-be-reduced-phase-3-clinical-trial-requi-f14b65e8cda6a57cPharma Surgeen2026-07-14T05:33:58.000ZBiosimilar Development Time and Costs to Be Reduced... Phase 3 Clinical Trial Requirements Easedhttps://www.pharmaradar360.com/article/roche-introduces-cobas-hepatitis-d-virus-hdv-test-the-first-fully-automated-diag-6791ad35ce55c8a8Pharma Surgeen2026-07-14T05:00:00.000ZRoche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitishttps://www.pharmaradar360.com/article/price-to-sales-forward-of-cspc-hunan-jingfeng-pharmaceutical-co-ltd-class-a-szse-da54d8f1cdba552bPharma Surgeen2026-07-14T04:55:14.000ZPrice to sales forward of CSPC Hunan Jingfeng Pharmaceutical Co Ltd Class A – SZSE:000908https://www.pharmaradar360.com/article/biogen-shares-rise-5-ahead-of-alzheimer-s-drug-trial-data-a9e00bb1a32bb3abPharma Surgeen2026-07-14T04:34:15.000ZBiogen Shares Rise 5% Ahead of Alzheimer's Drug Trial Datahttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-could-be-21-below-fair-value-on-vitiligo-tri-cc8bc47eb5b6460dPharma Surgeen2026-07-14T04:31:00.000ZTeva Pharmaceutical Industries (TEVA) Could Be 21% Below Fair Value On Vitiligo Trial Progresshttps://www.pharmaradar360.com/article/scientists-discover-why-peach-fuzz-can-suddenly-make-you-itch-68f4c1581a8cdfa6Pharma Surgeen2026-07-14T04:16:23.000ZScientists discover why peach fuzz can suddenly make you itchhttps://www.pharmaradar360.com/article/pune-fda-seizes-unlicensed-ayurvedic-medicines-worth-50-36-lakh-f5eb137ba94323b7Pharma Surgeen2026-07-14T04:08:40.000ZPune FDA Seizes Unlicensed Ayurvedic Medicines Worth ₹50.36 Lakhhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-kangmei-pharmaceutical-co-ltd-class-a-sse-60-53b2fa81478b0e91Pharma Surgeen2026-07-14T03:41:28.000ZEnterprise value to EBIT forward of Kangmei Pharmaceutical Co., Ltd Class A – SSE:600518https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-zhejiang-starry-pharmaceutical-co-ltd-cla-112fbbe4917a3440Pharma Surgeen2026-07-14T03:39:43.000ZEnterprise value to revenue forward of Zhejiang Starry Pharmaceutical Co., Ltd. Class A – SSE:603520https://www.pharmaradar360.com/article/veraxa-biotech-to-launch-ai-enabled-drug-discovery-collaboration-with-ardigen-to-ce4291ff1258bff4Pharma Surgeen2026-07-14T03:32:34.000ZVERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipelinehttps://www.pharmaradar360.com/article/peptron-chief-choi-buys-shares-signals-confidence-in-lilly-tie-up-and-tech-chosu-54dd5d5e4bf6e789Pharma Surgeen2026-07-14T03:20:00.000ZPeptron chief Choi buys shares, signals confidence in Lilly tie-up and tech - CHOSUNBIZhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-mycenax-biotech-inc-tpex-4726-62cd10bfb15f4dd1Pharma Surgeen2026-07-14T03:08:28.000ZEnterprise value to EBIT forward of Mycenax Biotech Inc. – TPEX:4726https://www.pharmaradar360.com/article/pharmaceutical-venture-announces-500m-expansion-in-northwest-austin-c995f0dab2ed0b3ePharma Surgeen2026-07-14T03:05:00.000ZPharmaceutical venture announces $500M expansion in Northwest Austinhttps://www.pharmaradar360.com/article/anzen-pmda-risk-communications-domperidone-oral-preparations-etc-posted-0081db583ce3911cPharma Surgeen2026-07-14T03:00:00.000Z[ANZEN]PMDA Risk Communications: Domperidone (oral preparations) etc. postedhttps://www.pharmaradar360.com/article/anzen-revisions-of-precautions-esomeprazole-magnesium-hydrate-etc-posted-33cdc31c2eb83d5bPharma Surgeen2026-07-14T03:00:00.000Z[ANZEN]Revisions of PRECAUTIONS: Esomeprazole Magnesium Hydrate, etc. postedhttps://www.pharmaradar360.com/article/biopharma-funds-surge-on-deals-and-drug-breakthroughs-eeb4b7fccc39b740Pharma Surgeen2026-07-14T02:57:47.000ZBiopharma Funds Surge on Deals and Drug Breakthroughshttps://www.pharmaradar360.com/article/large-block-sale-of-kubota-pharmaceutical-holdings-shares-8-19-4-32-by-evo-fund-e7fc5c5b832c362dPharma Surgeen2026-07-14T02:45:00.000ZLarge block sale of Kubota Pharmaceutical Holdings shares (8.19% → 4.32%) by Evo Fund and others.https://www.pharmaradar360.com/article/maharashtra-fda-crackdown-hits-dairy-and-gutkha-supply-chains-8b9bbf0bee203e06Pharma Surgeen2026-07-14T02:44:15.000ZMaharashtra FDA Crackdown Hits Dairy And Gutkha Supply Chainshttps://www.pharmaradar360.com/article/ireland-seeks-balance-on-biotech-incentives-and-patient-interests-c568aa6c4b563a31Pharma Surgeen2026-07-14T02:28:11.000ZIreland seeks balance on biotech incentives and patient interestshttps://www.pharmaradar360.com/article/australia-s-mesoblast-reaches-target-of-300-trial-patients-b08d6aedb1f7e8f5Pharma Surgeen2026-07-14T02:27:54.000ZAustralia's Mesoblast reaches target of 300 trial patientshttps://www.pharmaradar360.com/article/1-643-273d1d5fd0b6a2b9Pharma Surgeen2026-07-14T02:13:00.000Zがん遺伝子パネル検査による新たな治療選択が 予後改善を示唆 ―東北大学病院1,643例のリアルワールド解析―https://www.pharmaradar360.com/article/novo-nordisk-weaves-a-safety-net-hemophilia-drug-advances-as-glp-1-revenue-faces-26ad82d6654dfb45Pharma Surgeen2026-07-14T01:55:22.000ZNovo Nordisk Weaves a Safety Net: Hemophilia Drug Advances as GLP-1 Revenue Faces Halving in 2027https://www.pharmaradar360.com/article/astrazeneca-enters-exclusive-global-license-agreement-for-novel-oral-egfr-inhibi-4bd051a02d16cc16Pharma Surgeen2026-07-14T01:30:00.000ZAstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceuticalhttps://www.pharmaradar360.com/article/yale-scientists-found-a-hidden-network-inside-the-eye-2a44b968bcf01001Pharma Surgeen2026-07-14T01:15:50.000ZYale scientists found a hidden network inside the eyehttps://www.pharmaradar360.com/article/exercise-doesn-t-just-strengthen-the-heart-it-rewires-it-7595b70e5cdf8991Pharma Surgeen2026-07-14T00:47:33.000ZExercise doesn't just strengthen the heart. It rewires ithttps://www.pharmaradar360.com/article/mesoblast-tests-one-injection-for-chronic-low-back-pain-7a9c6ef16455c3eaPharma Surgeen2026-07-14T00:37:14.000ZMesoblast Tests One Injection for Chronic Low Back Painhttps://www.pharmaradar360.com/article/mesoblast-achieves-target-of-300-treated-patients-in-pivotal-phase-3-trial-for-c-bc3a89fabcc77bcePharma Surgeen2026-07-14T00:35:00.000ZMesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Painhttps://www.pharmaradar360.com/article/after-sc-now-wearables-first-fda-approval-for-on-body-injectable-anticancer-drug-82311c8de21fab09Pharma Surgeen2026-07-14T00:32:54.000ZAfter SC, Now Wearables: First FDA Approval for On-Body Injectable Anticancer Drug in the UShttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-6d9a96fbef59ff7fPharma Surgeen2026-07-14T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/local-sensory-innervation-shapes-anti-tumor-immunity-in-lung-cancer-e6f9cf01644c461aPharma Surgeen2026-07-14T00:00:00.000ZLocal sensory innervation shapes anti-tumor immunity in lung cancerhttps://www.pharmaradar360.com/article/a-framework-for-comparative-analysis-of-human-and-mouse-cortical-neuron-dendrite-7f7eee2b1bb3a372Pharma Surgeen2026-07-14T00:00:00.000ZA framework for comparative analysis of human and mouse cortical neuron dendrites in corresponding brain regionshttps://www.pharmaradar360.com/article/oxytocin-promotes-socially-triggered-cataplexy-ee0f2b457d5b6cd2Pharma Surgeen2026-07-14T00:00:00.000ZOxytocin promotes socially triggered cataplexyhttps://www.pharmaradar360.com/article/academia-should-recognize-community-partnerships-as-having-societal-impact-650544ff010281f0Pharma Surgeen2026-07-14T00:00:00.000ZAcademia should recognize community partnerships as having societal impacthttps://www.pharmaradar360.com/article/the-enhanced-games-and-the-normalization-of-doping-a-public-health-concern-68fb7aa09cb29766Pharma Surgeen2026-07-14T00:00:00.000ZThe Enhanced Games and the normalization of doping: a public health concernhttps://www.pharmaradar360.com/article/bird-flu-h5n1-in-australia-protect-australian-species-from-bird-flu-virus-030042679a3692bdPharma Surgeen2026-07-14T00:00:00.000ZBird flu H5N1 in Australia: protect Australian species from bird flu virushttps://www.pharmaradar360.com/article/ai-models-one-country-s-fears-become-everyone-s-constraint-e9791dbb857372daPharma Surgeen2026-07-14T00:00:00.000ZAI models: one country’s fears become everyone’s constrainthttps://www.pharmaradar360.com/article/mathematics-formula-found-on-maya-wall-rivals-insights-of-ancient-masters-1673cb355d21e5f4Pharma Surgeen2026-07-14T00:00:00.000ZMathematics formula found on Maya wall rivals insights of ancient mastershttps://www.pharmaradar360.com/article/climate-free-fall-why-the-biggest-risk-to-our-economies-is-yet-to-be-recognized-b8ed0f4bf7be20aaPharma Surgeen2026-07-14T00:00:00.000Z‘Climate free fall’: why the biggest risk to our economies is yet to be recognizedhttps://www.pharmaradar360.com/article/could-this-mysterious-disappearing-organ-hold-the-key-to-longevity-894c36e03c965976Pharma Surgeen2026-07-14T00:00:00.000ZCould this mysterious disappearing organ hold the key to longevity?https://www.pharmaradar360.com/article/my-research-on-mice-is-causing-me-stress-how-can-i-become-more-resilient-291b85064a62a0d4Pharma Surgeen2026-07-14T00:00:00.000ZMy research on mice is causing me stress. How can I become more resilient?https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-c272df6abcd101baPharma Surgeen2026-07-14T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-7998e052e6da1813Pharma Surgeen2026-07-14T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-ed05cea0d20bb7e9Pharma Surgeen2026-07-14T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-009aca5d301e76daPharma Surgeen2026-07-14T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-ef92a6bc782cc6f1Pharma Surgeen2026-07-14T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-9ae7520221afcd9fPharma Surgeen2026-07-14T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-1e9899ba523c063bPharma Surgeen2026-07-14T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-46288a9dd45bd33aPharma Surgeen2026-07-14T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-a8ddf1274a1143acPharma Surgeen2026-07-14T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-b494dfb2531a641aPharma Surgeen2026-07-14T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-fa6ad3fae62a3830Pharma Surgeen2026-07-14T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-7202823f5613640ePharma Surgeen2026-07-14T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-c3926f634be61873Pharma Surgeen2026-07-14T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-a177c56b0509a86ePharma Surgeen2026-07-14T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/psychedelic-drugs-considerations-for-clinical-investigations-guidance-for-indust-38698db823b8aa3ePharma Surgeen2026-07-14T00:00:00.000ZPsychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/considerations-for-potential-future-therapeutic-use-of-psychedelic-drugs-public-8bdd457f2ecdf21dPharma Surgeen2026-07-14T00:00:00.000ZConsiderations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Commentshttps://www.pharmaradar360.com/article/request-for-information-training-and-care-delivery-models-for-safe-administratio-c469aff76275a755Pharma Surgeen2026-07-14T00:00:00.000ZRequest for Information, Training and Care Delivery Models for Safe Administration of Potential FDA-Approved Psychedelic Therapies in Ambulatory Clinical Settingshttps://www.pharmaradar360.com/article/shane-lydon-m-d-decision-and-order-e3c4f39d8d50815ePharma Surgeen2026-07-14T00:00:00.000ZShane Lydon, M.D.; Decision and Orderhttps://www.pharmaradar360.com/article/barlow-st-clair-lynch-m-d-decision-and-order-335d365c1fe90bc5Pharma Surgeen2026-07-14T00:00:00.000ZBarlow St-Clair Lynch, M.D.; Decision and Orderhttps://www.pharmaradar360.com/article/david-enright-m-d-decision-and-order-9e1ba6f3451be035Pharma Surgeen2026-07-14T00:00:00.000ZDavid Enright, M.D.; Decision and Orderhttps://www.pharmaradar360.com/article/government-owned-inventions-availability-for-licensing-0762c7c858438582Pharma Surgeen2026-07-14T00:00:00.000ZGovernment-Owned Inventions; Availability for Licensinghttps://www.pharmaradar360.com/article/designated-placement-requirements-under-titles-iv-e-and-iv-b-for-lgbtqi-children-f598399f09c5a965Pharma Surgeen2026-07-14T00:00:00.000ZDesignated Placement Requirements Under Titles IV-E and IV-B for LGBTQI+ Children; Rescissionhttps://www.pharmaradar360.com/article/formal-meetings-between-fda-and-sponsors-or-requestors-of-over-the-counter-monog-2da188edbaea0bf5Pharma Surgeen2026-07-14T00:00:00.000ZFormal Meetings Between FDA and Sponsors or Requestors of Over-the-Counter Monograph Drugshttps://www.pharmaradar360.com/article/topical-dermatologic-corticosteroids-in-vivo-bioequivalence-guidance-for-industr-2e7d05a656365093Pharma Surgeen2026-07-14T00:00:00.000ZTopical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/national-vaccine-injury-compensation-program-list-of-petitions-received-772f73b828f20d6cPharma Surgeen2026-07-14T00:00:00.000ZNational Vaccine Injury Compensation Program; List of Petitions Receivedhttps://www.pharmaradar360.com/article/federal-register-notice-change-in-eligibility-period-for-refugee-cash-assistance-133526f517e8c6d6Pharma Surgeen2026-07-14T00:00:00.000ZFederal Register Notice: Change in Eligibility Period for Refugee Cash Assistance and Refugee Medical Assistancehttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-ab650734991ce728Pharma Surgeen2026-07-14T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/spadbarnskollaps-ovanligt-men-kan-fa-allvarliga-konsekvenser-cdedad4bf5d629f5Pharma Surgeen2026-07-14T00:00:00.000ZSpädbarnskollaps ovanligt men kan få allvarliga konsekvenserhttps://www.pharmaradar360.com/article/centrum-for-halsokriser-deltar-i-eu-mote-om-europas-beredskap-for-nasta-halsokri-8d179752b6172618Pharma Surgeen2026-07-14T00:00:00.000ZCentrum för hälsokriser deltar i EU-möte om Europas beredskap för nästa hälsokrishttps://www.pharmaradar360.com/article/comparative-effectiveness-of-glucagon-like-peptide-1-receptor-agonists-versus-or-704aa836331ce64dPharma Surgeen2026-07-14T00:00:00.000ZComparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabeteshttps://www.pharmaradar360.com/article/persistence-of-a-right-ovarian-ectopic-pregnancy-following-failure-of-the-intrau-d5c497e3ce46b608Pharma Surgeen2026-07-14T00:00:00.000ZPersistence of a Right Ovarian Ectopic Pregnancy Following Failure of the Intrauterine Component of a Spontaneous Heterotopic Pregnancy: A Rare Case Reporthttps://www.pharmaradar360.com/article/elevated-serum-endocan-concentrations-in-people-with-type-2-diabetes-and-diabeti-645e4d28473e76afPharma Surgeen2026-07-14T00:00:00.000ZElevated Serum Endocan Concentrations in People with Type 2 Diabetes and Diabetic Retinopathyhttps://www.pharmaradar360.com/article/neuroinflammatory-mechanisms-and-immunomodulatory-therapies-in-alzheimer-s-disea-ce3420c23b69dec1Pharma Surgeen2026-07-14T00:00:00.000ZNeuroinflammatory mechanisms and immunomodulatory therapies in Alzheimer's diseasehttps://www.pharmaradar360.com/article/clinical-radiological-and-functional-outcomes-of-open-long-bone-fractures-treate-a7b1de02dd6dcd49Pharma Surgeen2026-07-14T00:00:00.000ZClinical, Radiological, and Functional Outcomes of Open Long Bone Fractures Treated Primarily with the Limb Reconstruction System: A Prospective Observational Studyhttps://www.pharmaradar360.com/article/antibacteria-potential-of-urtica-dioica-leaf-extract-against-selected-clinical-b-927db17dcd8131abPharma Surgeen2026-07-14T00:00:00.000ZAntibacteria Potential of Urtica Dioica Leaf Extract Against Selected Clinical Bacterial Isolateshttps://www.pharmaradar360.com/article/life-autobiography-death-autobiography-a14e68eafd2e0377Pharma Surgeen2026-07-14T00:00:00.000ZLife autobiography – death autobiographyhttps://www.pharmaradar360.com/article/present-and-current-actual-8a9990c788ce39f2Pharma Surgeen2026-07-14T00:00:00.000ZPresent and current/actualhttps://www.pharmaradar360.com/article/rituals-and-repetitions-bcc171fb597e5872Pharma Surgeen2026-07-14T00:00:00.000ZRituals and repetitionshttps://www.pharmaradar360.com/article/the-shadow-zone-9b6ce4ee800e852bPharma Surgeen2026-07-14T00:00:00.000ZThe shadow zonehttps://www.pharmaradar360.com/article/introduction-6274c20eddd40000Pharma Surgeen2026-07-14T00:00:00.000ZIntroductionhttps://www.pharmaradar360.com/article/severe-insulin-deficient-diabetes-updated-review-of-epidemiology-biology-and-cli-82a06761b79badd8Pharma Surgeen2026-07-14T00:00:00.000ZSevere insulin-deficient diabetes: Updated review of epidemiology, biology, and clinical implicationshttps://www.pharmaradar360.com/article/two-novel-intronic-variants-in-i-abcb4-i-clinical-features-molecular-mechanisms-131b17e77e6c1b31Pharma Surgeen2026-07-14T00:00:00.000ZTwo novel intronic variants in <i>ABCB4</i> : Clinical features, molecular mechanisms, and literature reviewhttps://www.pharmaradar360.com/article/clinical-assessment-of-malnutrition-among-patients-with-alcoholic-liver-cirrhosi-6f07a54cb9996740Pharma Surgeen2026-07-14T00:00:00.000ZClinical assessment of malnutrition among patients with alcoholic liver cirrhosis: A single-center study in Southern Chinahttps://www.pharmaradar360.com/article/vonoprazan-amoxicillin-dual-therapy-for-i-helicobacter-pylori-i-eradication-clin-1785bb2a8b773896Pharma Surgeen2026-07-14T00:00:00.000ZVonoprazan-amoxicillin dual therapy for <i>Helicobacter pylori</i> eradication: Clinical, pharmacogenetic, and microbiome perspectiveshttps://www.pharmaradar360.com/article/subependymal-giant-cell-astrocytoma-without-clinical-evidence-of-tuberous-sclero-0dce59ff558fc66aPharma Surgeen2026-07-14T00:00:00.000ZSubependymal Giant Cell Astrocytoma Without Clinical Evidence of Tuberous Sclerosis Complex: Diagnostic and Molecular Insights—Case Reporthttps://www.pharmaradar360.com/article/imaging-based-risk-stratification-for-sudden-cardiac-death-in-hypertrophic-cardi-52ae79fd9b975634Pharma Surgeen2026-07-14T00:00:00.000ZImaging-Based Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy: Current Evidence and Clinical Perspectiveshttps://www.pharmaradar360.com/article/a-unique-presentation-of-bilateral-sprengel-s-deformity-with-a-horseshoe-configu-0199c4ef5dece1f4Pharma Surgeen2026-07-14T00:00:00.000ZA Unique Presentation of Bilateral Sprengel’s Deformity with a Horseshoe Configuration of Connected Omovertebral Bony Barshttps://www.pharmaradar360.com/article/comparative-trade-performance-of-india-s-pharmaceutical-industry-and-leading-glo-61de5af901fd6e8cPharma Surgeen2026-07-14T00:00:00.000ZComparative Trade Performance of India’s Pharmaceutical Industry and Leading Global Exporters: A Multi-Index Analysis at the Sectoral and Product Levelshttps://www.pharmaradar360.com/article/cord-blood-derived-versus-homologous-donor-platelet-rich-plasma-prp-in-early-kne-88c398f364574222Pharma Surgeen2026-07-14T00:00:00.000ZCord Blood-Derived Versus Homologous Donor Platelet-Rich Plasma (PRP) in Early Knee Osteoarthritis: A Single-Center, Randomized, Double-Blind Pilot Clinical Trialhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-needle-free-jet-injection-of-self-crosslinking-hyaluronic-e07948f6eb51629dPharma Surgeen2026-07-14T00:00:00.000ZEfficacy and safety of needle-free jet injection of self-crosslinking hyaluronic acid for facial fine wrinkles and skin texture: 12-week clinical outcomes in Asian womenhttps://www.pharmaradar360.com/article/application-and-governance-of-generative-artificial-intelligence-in-clinical-tea-50b65614ea86f0c9Pharma Surgeen2026-07-14T00:00:00.000ZApplication and Governance of Generative Artificial Intelligence in Clinical Teachinghttps://www.pharmaradar360.com/article/the-symptomatic-outcomes-in-patients-undergoing-cholecystectomy-for-gallstones-d-da659a82ae1e5e44Pharma Surgeen2026-07-14T00:00:00.000ZThe Symptomatic Outcomes in Patients Undergoing Cholecystectomy for Gallstones Diseasehttps://www.pharmaradar360.com/article/molecularly-guided-integration-of-pharmaceutical-chemistry-and-pharmaceutics-for-2844ff467392f948Pharma Surgeen2026-07-14T00:00:00.000ZMolecularly guided integration of pharmaceutical chemistry and pharmaceutics for next-generation drug delivery systemshttps://www.pharmaradar360.com/article/clinical-impact-and-prognostic-value-of-alzheimer-disease-biomarkers-in-the-very-02deefa6e4dbfdffPharma Surgeen2026-07-14T00:00:00.000ZClinical Impact and Prognostic Value of Alzheimer Disease Biomarkers in the Very Oldhttps://www.pharmaradar360.com/article/imminent-fracture-risk-contributing-mechanisms-risk-assessment-and-implications-6c7c9934d0858f33Pharma Surgeen2026-07-14T00:00:00.000ZImminent fracture risk: contributing mechanisms, risk assessment and implications for treatmenthttps://www.pharmaradar360.com/article/protective-d-a-feasibility-randomised-controlled-trial-examining-the-effect-of-a-dfde9ea95bea7ffcPharma Surgeen2026-07-14T00:00:00.000ZPROTECTIVE-D—a feasibility randomised controlled trial examining the effect of a positive mood intervention and vitamin D supplementation on the immunological responses to influenza vaccination in older adultshttps://www.pharmaradar360.com/article/molecular-and-clinical-characterization-of-a-pedigree-with-factor-xi-deficiency-2ca092d2586f3574Pharma Surgeen2026-07-14T00:00:00.000ZMolecular and clinical characterization of a pedigree with factor XI deficiency, including a novel missense variant (p.Cys200Phe): a case reporthttps://www.pharmaradar360.com/article/epigenome-wide-association-study-meta-analysis-of-wellbeing-d02ab7cc261f0866Pharma Surgeen2026-07-14T00:00:00.000ZEpigenome-wide association study meta-analysis of wellbeinghttps://www.pharmaradar360.com/article/a-clinical-trial-of-clomifene-citrate-in-men-with-infertility-f5386b69b58ce6bfPharma Surgeen2026-07-14T00:00:00.000ZA clinical trial of clomifene citrate in men with infertilityhttps://www.pharmaradar360.com/article/gilteritinib-and-chemotherapy-in-children-with-relapsed-refractory-i-flt3-i-itd-d2d9aa259cb3fe76Pharma Surgeen2026-07-14T00:00:00.000ZGilteritinib and chemotherapy in children with relapsed/refractory <i>FLT3</i> -ITD AML: results from the phase 1/2 SKIPPER trialhttps://www.pharmaradar360.com/article/letter-by-han-et-al-regarding-article-clinical-and-prognostic-significance-of-an-e0d9b239e69520c4Pharma Surgeen2026-07-14T00:00:00.000ZLetter by Han et al Regarding Article, “Clinical and Prognostic Significance of Anomalous Origin of a Coronary Artery in Adults”https://www.pharmaradar360.com/article/figure-2-from-development-of-glypican-3-targeting-antibody-drug-conjugates-for-h-afeaeccaf27d6696Pharma Surgeen2026-07-14T00:00:00.000ZFigure 2 from Development of Glypican 3–Targeting Antibody–Drug Conjugates for Hepatocellular Carcinoma Therapyhttps://www.pharmaradar360.com/article/figure-5-from-development-of-glypican-3-targeting-antibody-drug-conjugates-for-h-55e4beba84690bb1Pharma Surgeen2026-07-14T00:00:00.000ZFigure 5 from Development of Glypican 3–Targeting Antibody–Drug Conjugates for Hepatocellular Carcinoma Therapyhttps://www.pharmaradar360.com/article/supplementary-figure-s2-from-development-of-glypican-3-targeting-antibody-drug-c-637e4e7262872919Pharma Surgeen2026-07-14T00:00:00.000ZSupplementary Figure S2 from Development of Glypican 3–Targeting Antibody–Drug Conjugates for Hepatocellular Carcinoma Therapyhttps://www.pharmaradar360.com/article/supplementary-table-s1-from-development-of-glypican-3-targeting-antibody-drug-co-daf6995ef2caeaa9Pharma Surgeen2026-07-14T00:00:00.000ZSupplementary Table S1 from Development of Glypican 3–Targeting Antibody–Drug Conjugates for Hepatocellular Carcinoma Therapyhttps://www.pharmaradar360.com/article/supplementary-table-s2-from-development-of-glypican-3-targeting-antibody-drug-co-252c4bfbd86b68fbPharma Surgeen2026-07-14T00:00:00.000ZSupplementary Table S2 from Development of Glypican 3–Targeting Antibody–Drug Conjugates for Hepatocellular Carcinoma Therapyhttps://www.pharmaradar360.com/article/table-3-from-development-of-glypican-3-targeting-antibody-drug-conjugates-for-he-4c20f8ec1fe2acbaPharma Surgeen2026-07-14T00:00:00.000ZTable 3 from Development of Glypican 3–Targeting Antibody–Drug Conjugates for Hepatocellular Carcinoma Therapyhttps://www.pharmaradar360.com/article/efficacy-of-therapeutic-scp-uvc-scp-irradiation-in-reducing-bacterial-load-in-mi-169bf23520338e86Pharma Surgeen2026-07-14T00:00:00.000ZEfficacy of Therapeutic <scp>UVC</scp> Irradiation in Reducing Bacterial Load in Microbial Keratitis: A Retrospective Clinical Study in Veterinary Patientshttps://www.pharmaradar360.com/article/letter-to-the-editor-preserving-bedside-verification-and-clinical-uncertainty-in-7aa7e0a4330f4cebPharma Surgeen2026-07-14T00:00:00.000ZLetter to the Editor: Preserving Bedside Verification and Clinical Uncertainty in <scp>AI</scp> ‐Enabled Nursing Handoverhttps://www.pharmaradar360.com/article/efficacy-and-adherence-to-a-supervised-aerobic-exercise-training-intervention-in-d8f3844137656ed3Pharma Surgeen2026-07-14T00:00:00.000ZEfficacy and Adherence to a Supervised Aerobic Exercise Training Intervention in Night‐Shift Hospital Nurses: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/influenza-vaccine-effectiveness-against-outpatient-acute-respiratory-illness-wit-823588d30262ea08Pharma Surgeen2026-07-14T00:00:00.000ZInfluenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024–25 seasonhttps://www.pharmaradar360.com/article/dressings-and-wound-care-434d638fb18d13a5Pharma Surgeen2026-07-14T00:00:00.000ZDressings and wound carehttps://www.pharmaradar360.com/article/loneliness-and-alcohol-and-other-drug-use-outcomes-a-longitudinal-analysis-86c1faa8a5133713Pharma Surgeen2026-07-14T00:00:00.000ZLoneliness and Alcohol and Other Drug Use Outcomes: A Longitudinal Analysishttps://www.pharmaradar360.com/article/acceptance-of-a-smartwatch-based-clinical-monitoring-system-in-haemodialysis-a-m-ad6a2188409c71baPharma Surgeen2026-07-14T00:00:00.000ZAcceptance of a smartwatch-based clinical monitoring system in haemodialysis: A multicentre pilot implementation study of patients and nursing staff using an extended technology acceptance modelhttps://www.pharmaradar360.com/article/preclinical-characterization-and-phase-1-clinical-testing-of-targeting-mitochond-801499a2c00f84bbPharma Surgeen2026-07-14T00:00:00.000ZPreclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancerhttps://www.pharmaradar360.com/article/sociodemographic-and-clinical-predictors-in-patients-with-borderline-personality-b6a68861373c0369Pharma Surgeen2026-07-14T00:00:00.000ZSociodemographic and clinical predictors in patients with borderline personality disorder: a 12-month follow-up studyhttps://www.pharmaradar360.com/article/timing-dependent-modulation-of-testicular-ischemia-reperfusion-injury-by-febuxos-e1a15601986038e7Pharma Surgeen2026-07-14T00:00:00.000ZTiming-Dependent Modulation of Testicular Ischemia–Reperfusion Injury by Febuxostat, Amlodipine and Vitamin Ehttps://www.pharmaradar360.com/article/carbon-based-nanomaterials-as-versatile-platforms-for-the-development-of-drug-de-f7e88a379f08f8d2Pharma Surgeen2026-07-14T00:00:00.000ZCarbon based Nanomaterials as Versatile Platforms for the Development of Drug Delivery Systems: Current Trends and Future Prospectshttps://www.pharmaradar360.com/article/identification-and-characterization-of-putative-allosteric-sites-on-superoxide-d-c177da1f5b27f7f9Pharma Surgeen2026-07-14T00:00:00.000ZIdentification and characterization of putative allosteric sites on superoxide dismutases for use as species-specific drug targets to parasitic trypanosomatidshttps://www.pharmaradar360.com/article/a-novel-application-of-inhibitory-learning-theory-pediatric-retentive-encopresis-369fda3ca550cb84Pharma Surgeen2026-07-14T00:00:00.000ZA Novel Application of Inhibitory Learning Theory: Pediatric Retentive Encopresishttps://www.pharmaradar360.com/article/variables-associated-with-self-and-proxy-perceived-difficulties-in-independent-l-f7ae68d84434787dPharma Surgeen2026-07-14T00:00:00.000ZVariables associated with self- and proxy-perceived difficulties in independent living for patients with bipolar disorder and comorbid dementiahttps://www.pharmaradar360.com/article/mechanisms-and-clinical-evidence-of-dietary-patterns-in-axial-spondyloarthritis-14b391d19628f59ePharma Surgeen2026-07-14T00:00:00.000ZMechanisms and clinical evidence of dietary patterns in axial spondyloarthritishttps://www.pharmaradar360.com/article/combined-dmt-harmine-formulation-reduces-negative-self-referential-emotions-duri-35450a405137df11Pharma Surgeen2026-07-14T00:00:00.000ZCombined DMT–harmine formulation reduces negative self-referential emotions during social self-evaluation: a randomized placebo-controlled trial in healthy volunteershttps://www.pharmaradar360.com/article/clinical-outcome-assessment-in-der-kniechirurgie-f2eff54cb2c18829Pharma Surgeen2026-07-14T00:00:00.000ZClinical Outcome Assessment in der Kniechirurgiehttps://www.pharmaradar360.com/article/sgh-dti-drug-target-interaction-prediction-based-on-sequence-feature-enhancement-8288378869caaa20Pharma Surgeen2026-07-14T00:00:00.000ZSGH-DTI: Drug-Target Interaction Prediction Based on Sequence Feature Enhancement and Multi-hop Heterogeneous Graph Attentionhttps://www.pharmaradar360.com/article/chimnet-a-pose-aware-multimodal-hierarchical-network-with-hypergraph-interaction-33194b2cde5332efPharma Surgeen2026-07-14T00:00:00.000ZCHIMNet: A Pose-Aware Multimodal Hierarchical Network with Hypergraph Interaction and Confidence Gates for Drug-Target Affinity Predictionhttps://www.pharmaradar360.com/article/enhancing-sample-discrimination-drug-drug-interaction-prediction-based-on-bidire-c2cfcc969f69300bPharma Surgeen2026-07-14T00:00:00.000ZEnhancing Sample Discrimination: Drug-Drug Interaction Prediction Based on Bidirectional Event Semantics Guidancehttps://www.pharmaradar360.com/article/comparative-analysis-of-bioreactor-design-and-scale-up-for-cultivated-meat-using-839669e88c2d0ef7Pharma Surgeen2026-07-14T00:00:00.000ZComparative Analysis of Bioreactor Design and Scale‐Up for Cultivated Meat Using Monte Carlo‐Based Timescale Modelinghttps://www.pharmaradar360.com/article/model-informed-precision-dosing-in-paediatric-intensive-care-bridging-the-gap-be-eaa21a60dd4faa10Pharma Surgeen2026-07-14T00:00:00.000ZModel‐informed precision dosing in paediatric intensive care: Bridging the gap between pharmacological optimization and clinical benefithttps://www.pharmaradar360.com/article/otsuka-holdings-selected-as-a-constituent-of-esg-investment-indices-ftse4good-in-dc23ea6336b9b686Pharma Surgeen2026-07-14T00:00:00.000ZOtsuka Holdings Selected as a Constituent of ESG Investment Indices: FTSE4Good Index Series, FTSE JPX Blossom Japan Index, and FTSE JPX Blossom Japan Sector Relative Indexhttps://www.pharmaradar360.com/article/declaracion-del-comite-ejecutivo-del-cin-del-6-de-julio-de-2026-824fc3ee566cce96Pharma Surgeen2026-07-13T23:34:40.000ZDeclaración del Comité Ejecutivo del CIN del 6 de julio de 2026https://www.pharmaradar360.com/article/addf-statement-fda-approval-of-subcutaneous-starting-dose-for-leqembi-advances-a-4c8693d2ec84a727Pharma Surgeen2026-07-13T23:24:39.000ZADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer's Care Toward Combination Therapy Futurehttps://www.pharmaradar360.com/article/new-analysis-links-wegovy-to-a-rare-eye-condition-that-can-cause-sudden-permanen-498e2bd3cb7bb111Pharma Surgeen2026-07-13T23:00:00.000ZNew Analysis Links Wegovy to a Rare Eye Condition That Can Cause Sudden, Permanent Vision Losshttps://www.pharmaradar360.com/article/biomarin-pharmaceutical-bmrn-following-its-voxzogo-fda-filing-and-the-case-for-u-4d18225f05a06154Pharma Surgeen2026-07-13T22:16:14.000ZBioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluationhttps://www.pharmaradar360.com/article/fda-clears-first-at-home-starter-dose-for-alzheimer-s-drug-leqembi-sending-bioge-ca95109399230eccPharma Surgeen2026-07-13T22:05:00.000ZFDA Clears First At-Home Starter Dose for Alzheimer’s Drug Leqembi, Sending Biogen Shares Up 5%https://www.pharmaradar360.com/article/abbvie-pharmaceutical-project-moves-forward-in-durham-huge-deal-ef00f22477841b99Pharma Surgeen2026-07-13T21:52:20.000ZAbbVie pharmaceutical project moves forward in Durham: 'Huge deal'https://www.pharmaradar360.com/article/law-schools-adapting-to-rising-applications-ai-s-growing-influence-eea49f154562a73bPharma Surgeen2026-07-13T21:29:59.000ZLaw schools adapting to rising applications, AI's growing influencehttps://www.pharmaradar360.com/article/this-new-bill-hopes-to-put-the-brakes-on-financial-fraud-targeting-older-america-7a44a9e4c9312e63Pharma Surgeen2026-07-13T21:29:30.000ZThis new bill hopes to 'put the brakes' on financial fraud targeting older Americanshttps://www.pharmaradar360.com/article/how-s-the-water-researchers-try-to-gauge-public-perception-of-twin-cities-lakes-9c2625e17699d2b2Pharma Surgeen2026-07-13T21:28:50.000ZHow’s the water? Researchers try to gauge public perception of Twin Cities lakes.https://www.pharmaradar360.com/article/russian-billionaire-wins-fight-to-boot-manager-of-biotech-fund-6c979e95ee5f689ePharma Surgeen2026-07-13T21:12:40.000ZRussian Billionaire Wins Fight to Boot Manager of Biotech Fundhttps://www.pharmaradar360.com/article/boulder-biotech-unloads-muscular-dystrophy-drug-for-up-to-2-65-billion-ac2a7b01c5497d6bPharma Surgeen2026-07-13T21:07:00.000ZBoulder biotech unloads muscular dystrophy drug for up to $2.65 billionhttps://www.pharmaradar360.com/article/alopecia-drug-bempikibart-clears-phase-2a-bar-works-in-patients-jak-inhibitors-f-92ae93ad109ada5dPharma Surgeen2026-07-13T20:49:44.000ZAlopecia Drug Bempikibart Clears Phase 2a Bar, Works in Patients JAK Inhibitors Failedhttps://www.pharmaradar360.com/article/psychedelics-fda-offers-clarifications-compromises-in-final-clinical-trial-guida-61a751aa995dd02cPharma Surgeen2026-07-13T20:49:00.000ZPsychedelics: FDA offers clarifications, compromises in final clinical trial guidancehttps://www.pharmaradar360.com/article/big-pharma-s-300-billion-patent-problem-fuels-biotech-deals-bcc08da5a3fae4edPharma Surgeen2026-07-13T20:48:38.000ZBig Pharma's $300 Billion Patent Problem Fuels Biotech Dealshttps://www.pharmaradar360.com/article/novartis-carrie-bracco-says-flexibility-in-biomanufacturing-is-the-most-underadd-5ce0bd875b7049a7Pharma Surgeen2026-07-13T20:22:54.000ZNovartis’ Carrie Bracco Says Flexibility in Biomanufacturing is the Most Underaddressed Need for Emerging Biotech Companieshttps://www.pharmaradar360.com/article/new-autologous-t-cell-therapy-offers-hope-for-children-with-brain-tumors-52e0d33b2719579dPharma Surgeen2026-07-13T20:11:33.000ZNew autologous T cell therapy offers hope for children with brain tumorshttps://www.pharmaradar360.com/article/notifications-on-data-integrity-8f0694aefbbd1a22Pharma Surgeen2026-07-13T19:50:16.000ZNotifications on Data Integrityhttps://www.pharmaradar360.com/article/ems-lanca-plataforma-digital-gratuita-para-ampliar-acesso-a-bula-de-remedios-de-9dac8ce4a7196566Pharma Surgeen2026-07-13T19:48:35.000ZEMS lança plataforma digital gratuita para ampliar acesso à bula de remédios de todo o mercado brasileiro e promover autocuidadohttps://www.pharmaradar360.com/article/abre-la-convocatoria-a-la-muestra-universidad-memoria-y-democracia-d775945fea217f39Pharma Surgeen2026-07-13T19:47:09.000ZAbre la convocatoria a la Muestra “Universidad, Memoria y Democracia”https://www.pharmaradar360.com/article/samd-compliance-in-your-dev-tools-2998ecebcde9a872Pharma Surgeen2026-07-13T19:45:00.000ZSaMD compliance in your dev toolshttps://www.pharmaradar360.com/article/farmaceutica-ems-renova-patrocinio-comvolei-renata-pelo-terceiro-ano-consecutivo-0ec1d816438449b0Pharma Surgeen2026-07-13T19:35:18.000ZFarmacêutica EMS renova patrocínio comVôlei Renata pelo terceiro ano consecutivohttps://www.pharmaradar360.com/article/senate-aging-panel-probes-foreign-drug-supply-control-9b159211935ad5bfPharma Surgeen2026-07-13T19:33:21.000ZSenate Aging Panel Probes Foreign Drug Supply Controlhttps://www.pharmaradar360.com/article/techcyte-announces-go-live-of-fusion-parasitology-suite-at-sonora-quest-laborato-f339efbc181c2f30Pharma Surgeen2026-07-13T19:31:23.000ZTechcyte Announces Go-Live of Fusion Parasitology Suite at Sonora Quest Laboratorieshttps://www.pharmaradar360.com/article/pro-life-ag-suggests-a-reason-why-the-trump-admin-hasn-t-cracked-down-on-the-abo-d343313cd64b7c04Pharma Surgeen2026-07-13T19:30:53.000ZPro-Life AG Suggests a Reason Why the Trump Admin Hasn’t Cracked Down on the Abortion Pillhttps://www.pharmaradar360.com/article/hhs-va-announce-bold-comprehensive-partnership-to-advance-rapid-acting-mental-he-526d1c875d73bdfePharma Surgeen2026-07-13T19:30:00.000ZHHS & VA Announce Bold, Comprehensive Partnership to Advance Rapid-Acting Mental Health Treatments for Veteranshttps://www.pharmaradar360.com/article/global-health-policy-on-the-move-impact-of-mfn-and-eu-hta-reform-on-global-and-r-8d866c8df2a63700Pharma Surgeen2026-07-13T19:27:46.000ZGlobal Health Policy on the Move: Impact of MFN and EU HTA reform on Global and Regional Accesshttps://www.pharmaradar360.com/article/a-visit-with-the-africa-clinical-research-network-cae9cd532a49ddbfPharma Surgeen2026-07-13T19:26:57.000ZA Visit with the Africa Clinical Research Networkhttps://www.pharmaradar360.com/article/guest-blog-trusting-what-i-knew-about-my-body-25d68039e43b4a46Pharma Surgeen2026-07-13T19:12:19.000ZGuest Blog: Trusting What I Knew About My Bodyhttps://www.pharmaradar360.com/article/profits-over-safety-james-uthmeier-launches-probe-into-cancer-linked-food-additi-291bf87a365874abPharma Surgeen2026-07-13T19:12:17.000Z‘Profits over safety’: James Uthmeier launches probe into cancer-linked food additivehttps://www.pharmaradar360.com/article/tauber-recorrio-las-obras-avanzadas-de-la-facultad-de-trabajo-social-30e56dea7af9d580Pharma Surgeen2026-07-13T19:02:41.000ZTauber recorrió las obras avanzadas de la facultad de Trabajo Socialhttps://www.pharmaradar360.com/article/fda-issues-crl-to-elevar-therapeutics-pharmexec-ec8dea13bf780f41Pharma Surgeen2026-07-13T19:02:37.000ZFDA Issues CRL to Elevar Therapeutics | PharmExechttps://www.pharmaradar360.com/article/rassegnastampa-coltivare-gli-affetti-una-medicina-gratuita-per-un-cervello-felic-f2fe4e9264c11c8bPharma Surgeen2026-07-13T18:25:00.000Z#RASSEGNASTAMPA. Coltivare gli affetti: una medicina gratuita per un "cervello felice". Marco Locatelli si racconta nella serie "Grandi Medici" del Corriere della Serahttps://www.pharmaradar360.com/article/fda-accepts-biomarin-application-for-full-voxzogo-approval-ab766018c6300924Pharma Surgeen2026-07-13T18:21:50.000ZFDA accepts BioMarin application for full VOXZOGO approvalhttps://www.pharmaradar360.com/article/de-la-unlp-a-los-premios-oscar-51c5ed9314cd00e0Pharma Surgeen2026-07-13T18:21:25.000ZDe la UNLP a los Premios Oscarhttps://www.pharmaradar360.com/article/vino-de-la-costa-la-alianza-entre-productores-y-la-unlp-que-cambio-su-destino-6ba5fbf32200781ePharma Surgeen2026-07-13T18:20:57.000ZVino de la Costa: la alianza entre productores y la UNLP que cambió su destinohttps://www.pharmaradar360.com/article/learning-from-the-last-decade-of-gene-therapies-fd044e67a233a236Pharma Surgeen2026-07-13T18:20:44.000ZLearning from the last decade of gene therapieshttps://www.pharmaradar360.com/article/directores-academicos-dialogan-sobre-plan-estrategico-uc-5490a6590b4f901dPharma Surgeen2026-07-13T17:43:37.000ZDirectores académicos dialogan sobre Plan Estratégico UChttps://www.pharmaradar360.com/article/own-regeneron-for-biotech-growth-incyte-is-making-its-case-e9451da956c38c8aPharma Surgeen2026-07-13T17:36:36.000ZOwn Regeneron For Biotech Growth? Incyte Is Making Its Case.https://www.pharmaradar360.com/article/malvern-s-ocugen-strikes-up-to-255m-licensing-deal-4cc26ee883344124Pharma Surgeen2026-07-13T17:22:00.000ZMalvern's Ocugen strikes up to $255M licensing dealhttps://www.pharmaradar360.com/article/attention-q32-bio-investors-take-profits-before-qttb-shares-crash-again-c1c99153b35b697aPharma Surgeen2026-07-13T17:18:51.000ZAttention Q32 Bio investors: take profits before QTTB shares crash againhttps://www.pharmaradar360.com/article/hub-and-spoke-drug-manufacturing-set-to-benefit-from-new-fda-rule-42e822607c51d3d8Pharma Surgeen2026-07-13T17:12:51.000Z“Hub-and-spoke” drug manufacturing set to benefit from new FDA rulehttps://www.pharmaradar360.com/article/fda-recalls-and-warnings-generic-adderall-xr-mix-up-subpotent-levothyroxine-mori-9969023bac7a1739Pharma Surgeen2026-07-13T16:36:03.000ZFDA Recalls and Warnings: Generic Adderall XR Mix-Up, Subpotent Levothyroxine, Moringa Supplements Tainted with Salmonellahttps://www.pharmaradar360.com/article/agenus-announces-oversubscribed-private-placement-of-up-to-340-million-to-advanc-346ba7475d7dd6ccPharma Surgeen2026-07-13T16:31:54.000ZAgenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancerhttps://www.pharmaradar360.com/article/ocugen-signs-255m-mena-licensing-deal-for-ocu400-gene-therapy-to-treat-retinitis-1d9e8f24d600ab20Pharma Surgeen2026-07-13T16:31:00.000ZOcugen Signs $255M MENA Licensing Deal for OCU400 Gene Therapy to Treat Retinitis Pigmentosahttps://www.pharmaradar360.com/article/retatrutide-posts-strong-phase-3-results-in-type-2-diabetes-but-is-it-truly-the-0ba538588d183a53Pharma Surgeen2026-07-13T16:24:29.000ZRetatrutide Posts Strong Phase 3 Results in Type 2 Diabetes, but Is It Truly the Next Generation Beyond GLP-1?https://www.pharmaradar360.com/article/se-realizo-la-primera-reunion-del-consejo-social-de-la-gestion-2026-2030-c287dc68f314e9aePharma Surgeen2026-07-13T16:23:15.000ZSe realizó la primera reunión del Consejo Social de la gestión 2026-2030https://www.pharmaradar360.com/article/la-unlp-celebro-el-dia-de-la-independencia-dad07995c1ab07a6Pharma Surgeen2026-07-13T16:22:21.000ZLa UNLP celebró el día de la Independenciahttps://www.pharmaradar360.com/article/bofa-raises-krystal-biotech-stock-price-target-on-vyjuvek-growth-11786a2e16c395abPharma Surgeen2026-07-13T16:13:25.000ZBofA raises Krystal Biotech stock price target on Vyjuvek growthhttps://www.pharmaradar360.com/article/what-is-an-aortic-dissection-d857f4f802b4130aPharma Surgeen2026-07-13T16:00:00.000ZWhat is an Aortic Dissection?https://www.pharmaradar360.com/article/criteriacaixa-targets-300m-for-biotech-and-tech-by-2030-03fcf8ba89a580ecPharma Surgeen2026-07-13T15:58:34.000ZCriteriaCaixa targets €300M for biotech and tech by 2030https://www.pharmaradar360.com/article/pune-fda-seizes-suspected-adulterated-food-stock-worth-37-61-lakh-across-seven-l-26406810abc8182aPharma Surgeen2026-07-13T15:53:02.000ZPune: FDA Seizes Suspected Adulterated Food Stock Worth ₹37.61 Lakh Across Seven Locationshttps://www.pharmaradar360.com/article/ai-must-be-frames-as-a-force-multiplier-not-as-a-substitute-d662fe286eb70c1bPharma Surgeen2026-07-13T15:52:59.000ZAI must be frames as a force multiplier, not as a substitutehttps://www.pharmaradar360.com/article/industry-analysis-says-innovative-medicines-deliver-six-fold-return-in-greece-1c95a9c4133dad82Pharma Surgeen2026-07-13T15:45:00.000ZIndustry analysis says innovative medicines deliver six-fold return in Greecehttps://www.pharmaradar360.com/article/how-one-man-s-gift-shapes-a-new-generation-of-philosophy-scholars-c6eb9fcee24e908ePharma Surgeen2026-07-13T15:40:54.000ZHow one man’s gift shapes a new generation of philosophy scholarshttps://www.pharmaradar360.com/article/ocugen-signs-ocu400-mena-license-agreement-af4e7494879b44eePharma Surgeen2026-07-13T15:38:00.000ZOcugen signs OCU400 MENA license agreementhttps://www.pharmaradar360.com/article/fda-s-latest-onshoring-move-homes-in-on-streamlined-facility-registration-foreig-863b180911a9389dPharma Surgeen2026-07-13T15:37:17.000ZFDA's latest onshoring move homes in on streamlined facility registration, foreign plant scrutinyhttps://www.pharmaradar360.com/article/register-to-make-submissions-to-the-mhra-2bf64e65d9b9a3f9Pharma Surgeen2026-07-13T15:34:24.000ZRegister to make submissions to the MHRAhttps://www.pharmaradar360.com/article/fda-takes-first-step-toward-de-facto-ad-ban-what-to-know-43ecaf8f9956e8daPharma Surgeen2026-07-13T15:08:31.000ZFDA takes first step toward ‘de facto’ ad ban: What to knowhttps://www.pharmaradar360.com/article/world-patient-safety-congress-americas-2026-1c676e20058ed072Pharma Surgeen2026-07-13T15:05:23.000ZWorld Patient Safety Congress Americas 2026https://www.pharmaradar360.com/article/here-s-how-much-100-invested-in-state-street-spdr-s-p-biotech-etf-20-years-ago-w-3a4aaa8a7fc82147Pharma Surgeen2026-07-13T15:04:00.000ZHere's How Much $100 Invested In State Street SPDR S&P Biotech ETF 20 Years Ago Would Be Worth Todayhttps://www.pharmaradar360.com/article/curso-para-collaborative-online-international-learning-organizado-por-obreal-y-c-f65363f7127c9ac2Pharma Surgeen2026-07-13T15:03:49.000ZCurso para Collaborative Online International Learning organizado por OBREAL Y CSUCAhttps://www.pharmaradar360.com/article/mikiko-sodeoka-elected-as-international-honorary-member-of-the-american-academy-22f3a2db0eecc53cPharma Surgeen2026-07-13T15:00:00.000ZMikiko Sodeoka elected as International Honorary Member of the American Academy of Arts & Scienceshttps://www.pharmaradar360.com/article/fda-advances-real-time-clinical-trials-what-it-means-for-ai-driven-drug-developm-7f88dd1244d74b10Pharma Surgeen2026-07-13T14:59:05.000ZFDA Advances Real-Time Clinical Trials: What It Means for AI-Driven Drug Developmenthttps://www.pharmaradar360.com/article/ai-enabled-drug-discovery-collaboration-with-veraxa-biotech-to-support-growing-b-98b0460c63c86fa2Pharma Surgeen2026-07-13T14:55:00.000ZAI-enabled drug discovery collaboration with VERAXA biotech to support growing BiTAC® pipelinehttps://www.pharmaradar360.com/article/300-million-for-iberian-biotech-and-deeptech-as-criteriacaixa-rebrands-its-vc-ar-cb37eb5cfb792724Pharma Surgeen2026-07-13T14:50:51.000Z€300 million for Iberian BioTech and DeepTech as CriteriaCaixa rebrands its VC armhttps://www.pharmaradar360.com/article/fda-accepts-nda-for-mezigdomide-combo-in-r-r-multiple-myeloma-b09e100332b1952aPharma Surgeen2026-07-13T14:49:51.000ZFDA Accepts NDA for Mezigdomide Combo in R/R Multiple Myelomahttps://www.pharmaradar360.com/article/ocugen-inc-announces-binding-term-sheet-with-roots-pharmaceutical-to-license-ocu-a444f01ba65ef119Pharma Surgeen2026-07-13T14:48:45.000ZOcugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africahttps://www.pharmaradar360.com/article/biogen-stock-is-upgraded-to-buy-ahead-of-key-alzheimer-s-drug-study-details-b70d1a7e4fab3b63Pharma Surgeen2026-07-13T14:46:00.000ZBiogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Detailshttps://www.pharmaradar360.com/article/agenus-agen-stock-jumps-13-on-major-340m-financing-agreement-67f434def7d1747cPharma Surgeen2026-07-13T14:42:37.000ZAgenus (AGEN) Stock Jumps 13% on Major $340M Financing Agreementhttps://www.pharmaradar360.com/article/world-patient-safety-congress-europe-2026-9514579105a62489Pharma Surgeen2026-07-13T14:41:22.000ZWorld Patient Safety Congress Europe 2026https://www.pharmaradar360.com/article/122-mcgill-research-projects-awarded-30-million-in-nserc-discovery-grants-fundin-250d19328c7955edPharma Surgeen2026-07-13T14:40:46.000Z122 McGill research projects awarded $30 million in NSERC Discovery Grants fundinghttps://www.pharmaradar360.com/article/cordis-project-targeted-genetic-manipulation-of-muscle-stem-cells-in-vivo-toward-003e1b741673a4d7Pharma Surgeen2026-07-13T14:39:58.000ZCORDIS project: Targeted Genetic Manipulation of Muscle Stem Cells in vivo Towards New Treatment Strategies Against Muscular Dystrophieshttps://www.pharmaradar360.com/article/cordis-project-celltuned-ai-driven-regulatory-genomics-for-precision-therapy-03449abd18206465Pharma Surgeen2026-07-13T14:39:39.000ZCORDIS project: CellTuned: AI-driven regulatory genomics for precision therapy